Review of clinical trials in intraoperative molecular imaging during cancer surgery

Most solid cancers are treated by surgical resections to reduce the burden of disease. Surgeons often face the challenge of detecting small areas of residual neoplasm after resection or finding small primary tumors for the initial resection. Intraoperative molecular imaging (IMI) is an emerging tech...

Full description

Saved in:
Bibliographic Details
Published inJournal of biomedical optics Vol. 24; no. 12; p. 120901
Main Authors Lee, John Y. K, Cho, Steve S, Stummer, Walter, Tanyi, Janos L, Vahrmeijer, Alexander L, Rosenthal, Eben, Smith, Barbara, Henderson, Eric, Roberts, David W, Lee, Amy, Hadjipanayis, Constantinos G, Bruce, Jeffrey N, Newman, Jason G, Singhal, Sunil
Format Journal Article
LanguageEnglish
Published United States Society of Photo-Optical Instrumentation Engineers 01.12.2019
S P I E - International Society for
Subjects
Brain cancer
Breast cancer
Cancer
Clinical trials
Contrast agents
Contrast media
FDA approval
Medical imaging
Neoplasia
New technology
Ovarian cancer
Review Papers
Surgeons
Surgery
United States > US
Europe
fluorescence-guided surgery
intraoperative visualization
molecular imaging
tumor surgery
Online AccessGet full text

Cover

More Information
Summary:Most solid cancers are treated by surgical resections to reduce the burden of disease. Surgeons often face the challenge of detecting small areas of residual neoplasm after resection or finding small primary tumors for the initial resection. Intraoperative molecular imaging (IMI) is an emerging technology with the potential to dramatically improve cancer surgery operations by allowing surgeons to better visualize areas of neoplasm using fluorescence imaging. Over the last two years, two molecular optical contrast agents received U.S. Food and Drug Administration approval, and several more drugs are now on the horizon. Thus a conference was organized at the University of Pennsylvania to bring together oncologic surgeons from different specialties to discuss the current clinical status of IMI trials with a specific focus on phase 2 and phase 3 studies. In addition, phase 1 and experimental trials were also discussed briefly, to highlight other novel techniques. Our review summarizes the discussions from the conference and delves into the types of cancers discussed, different contrast agents in human trials, and the clinical value being studied.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1083-3668
1560-2281
1560-2281
DOI:10.1117/1.JBO.24.12.120901